Stockwinners Market Radar for February 02, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

14:23 EST Corvus Pharmaceuticals presents updated data from Phase 1/1b trial of CPI-818 - Corvus Pharmaceuticals announced updated results from its Phase 1/1b clinical trial of CPI-818, the company's ITK-inhibitor, which were presented in an oral presentation at the 12th Annual T-Cell Lymphoma Forum in La Jolla, California, taking place January 30 to February 1, 2020. The CPI-818 Phase 1/1b study is currently enrolling patients with several types of advanced, refractory T-cell lymphomas, including peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell lymphoma, cutaneous T-cell lymphoma and other T-cell lymphomas. The study employs an adaptive, expansion cohort design to select the dose and evaluate the safety, pharmacokinetics, target occupancy, biomarkers and efficacy of CPI-818. The initial phase of the trial is evaluating escalating doses in successive cohorts of patients in order to determine the optimum dose. A second phase will evaluate safety and tumor response to this optimum dose of CPI-818 in disease-specific patient cohorts that may be expanded based on early signs of efficacy. The study is enrolling patients at major medical centers in the United States, Australia and South Korea. Pre-clinical Characterization and Interim Results of a Phase I/Ib Dose-Escalation Trial in Patients with Relapsed/Refractory T-Cell Lymphoma, included: 16 patients have been enrolled in the first four dose cohorts in the initial phase of the trial, receiving a 100 mg, 200 mg, 400 mg or 600 mg oral dose of CPI-818 two times per day, with no dose limiting toxicities and no grade 3 or 4 treatment related adverse events observed. The median patient follow-up period is now three months, with 11 patients remaining on therapy. One patient with CTCL treated with the 200 mg dose of CPI-818 achieved a reduction in lymphadenopathy and improvement of PET scan imaging; another patient with CTCL receiving the 400 mg dose has exhibited improvement in cutaneous disease. These patients continue on therapy. The results from the pharmacokinetic and occupancy studies for the first 12 patients have been in-line with expectations, with increasing target occupancy with higher doses based on available data from the 100 mg, 200 mg, and 400 mg doses. The maximum target occupancy has not yet been achieved in the first three dose cohorts, but the Company continues to anticipate that maximum target occupancy will be achieved in the 600 mg cohort, which was recently initiated.

08:29 EST PG&E submits Chapter 11 Plan of Reorganization testimony to state regulators - PG&E and Pacific Gas and Electric Company submitted regulatory and court filings outlining the key elements of the company's updated Chapter 11 Plan of Reorganization. PG&E submitted testimony in the California Public Utilities Commission Plan of Reorganization proceeding and filed its updated Plan with the Bankruptcy Court. Based on these filings, PG&E remains on track to have its Chapter 11 Plan confirmed by June 30, 2020, the deadline for participating in the state's new go-forward wildfire fund. Upon emergence from Chapter 11, PG&E will be a financially stable company positioned to continue prioritizing safe operations and customer focus while meeting California's energy needs and clean energy goals in a changed climate. As explained in its testimony, PG&E believes its Plan meets both the letter and spirit of Assembly Bill 1054, including being rate neutral on average to customers. The Plan also addresses concerns the Governor raised in his December 13, 2019, public letter to the company. PG&E appreciates the Governor's input and is open to further discussions with the Governor's Office and other stakeholders should they have additional input as the process unfolds. PG&E looks forward to participating fully in the CPUC's proceeding to review its updated Plan. Key updated safety, governance, and operational elements of the Plan include: Refreshing the Boards of Directors of PG&E Corporation and Pacific Gas and Electric Company so that the Boards will have the necessary expertise and skills to oversee the company post-emergence; Implementing a plan to regionalize the company's operations and its infrastructure to enhance the company's focus on local communities and customers; Further strengthening PG&E's corporate governance by appointing an independent safety advisor after the term of the court-appointed Federal Monitor expires; Establishing a newly expanded role of Chief Risk Officer who will report directly to the PG&E Corporation CEO and have oversight of risks associated with PG&E's operations; Establishing a newly expanded role of Chief Safety Officer who will report directly to the PG&E Corporation CEO and have oversight of PG&E's strategy to further improve public and workforce safety; Forming an Independent Safety Oversight Committee with non-PG&E employees to provide independent review of the company's operations, including safety and regulatory compliance, safety leadership, and operational performance; Committing to enhanced safety metrics and stricter regulatory oversight with escalating enforcement mechanisms; Reforming executive compensation to further tie it to safety performance; and Assuming all pension obligations, other employee obligations, and collective bargaining agreements with labor unions, and all power purchase agreements and community choice aggregation servicing agreements. Key updated financial elements of the Plan include: Paying value in excess of $25B to wildfire victims through the settlements reached with individual victims, subrogation claimants, and public entities; and Emerging with a financing structure that protects customer rates and positions the company for long term success. This includes saving PG&E's customers nearly $1B through the previously announced settlement with noteholders and contributing shareholder credits of approximately $8B so that the plan is neutral on average to customers.